XML 27 R121.htm IDEA: XBRL DOCUMENT v2.4.0.8
Financial Instruments and Fair Value Measurements (Schedules of Concentration of Risk) (Detail)
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 28, 2014
Mar. 29, 2013
Mar. 28, 2014
Mar. 29, 2013
Sep. 27, 2013
Sep. 28, 2012
Sep. 30, 2011
Distributor Concentration Risk | Net Sales Attributable to Distributors | Cardinal Health, Inc.
             
Concentration Risk [Line Items]              
Concentration risk, percentage 15.00% 20.00% 18.00% 20.00% 18.00% 19.00% 19.00%
Distributor Concentration Risk | Net Sales Attributable to Distributors | McKesson Corporation
             
Concentration Risk [Line Items]              
Concentration risk, percentage 15.00% 19.00% 15.00% 16.00% 15.00% 14.00% 13.00%
Distributor Concentration Risk | Net Sales Attributable to Distributors | Amerisource Bergen Corporation
             
Concentration Risk [Line Items]              
Concentration risk, percentage 10.00% 6.00% 11.00% 7.00% 9.00% 9.00% 10.00%
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Cardinal Health, Inc.
             
Concentration Risk [Line Items]              
Concentration risk, percentage     20.00%   18.00% 19.00%  
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | McKesson Corporation
             
Concentration Risk [Line Items]              
Concentration risk, percentage     23.00%   22.00% 20.00%  
Distributor Concentration Risk | Accounts Receivable Attributable to Distributors | Amerisource Bergen Corporation
             
Concentration Risk [Line Items]              
Concentration risk, percentage     13.00%   14.00% 10.00%  
Product Concentration Risk | Net Sales Attributable to Products | Optiray (CMDS)
             
Concentration Risk [Line Items]              
Concentration risk, percentage 13.00% 13.00% 13.00% 14.00% 14.00% 17.00% 19.00%
Product Concentration Risk | Net Sales Attributable to Products | Acetaminophen Products (API) [Member]
             
Concentration Risk [Line Items]              
Concentration risk, percentage 9.00% 10.00% 8.00% 10.00% 10.00% 11.00% 11.00%
Product Concentration Risk | Net Sales Attributable to Products | Methylphenidate ER (Specialty Generics)
             
Concentration Risk [Line Items]              
Concentration risk, percentage 8.00% 11.00% 9.00% 7.00%